Capecitabine

Capecitabine is an oral chemotherapy pill that the body converts into 5-fluorouracil (5-FU), a drug that interferes with cancer cells' ability to copy their DNA. Because it is taken at home as a tablet rather than given by IV infusion, it is sometimes used when patients need a more convenient or less intensive option. It is most commonly approved for colorectal, breast, gastric, and pancreatic cancers.

Origin

Capecitabine was developed by Roche and approved by the FDA in 1998 under the brand name Xeloda. It was engineered as a prodrug of 5-fluorouracil, meaning it is inactive when swallowed and is converted to its active form through a three-step enzymatic process, with the final step occurring preferentially in tumor tissue.

Significance in Asbestos Context

Capecitabine is not a standard first-line treatment for mesothelioma. The established regimens are platinum-based chemotherapy (cisplatin or carboplatin with pemetrexed) and, more recently, immunotherapy combinations such as nivolumab plus ipilimumab. Capecitabine may appear in a mesothelioma treatment plan in specific situations: as part of a clinical trial, in combination with other agents such as gemcitabine, or as a later-line option after standard therapies have stopped working. For patients with peritoneal mesothelioma, it has occasionally been studied in combination regimens. If your oncologist proposes capecitabine, ask specifically why this drug is being chosen over standard mesothelioma protocols and whether a clinical trial might offer additional options.

Example Sentence

When the mesothelioma progressed after pemetrexed and cisplatin, her oncologist discussed adding capecitabine as part of a second-line regimen.

Related Terms

Chemotherapy, Pemetrexed, 5-Fluorouracil, Malignant Mesothelioma, Prodrug, Clinical Trial

Notes

• Ask your oncologist whether capecitabine is being used as part of a standard mesothelioma protocol, off-label, or within a clinical trial, and request the supporting evidence for its use in your specific situation.
• Watch for hand-foot syndrome (painful redness, swelling, peeling on the palms and soles), diarrhea, and mouth sores; report these early because dose adjustments can prevent serious complications.
• Patients with a DPD (dihydropyrimidine dehydrogenase) enzyme deficiency can have severe, even fatal reactions to capecitabine; ask whether DPD testing is appropriate before starting treatment.
• Keep a written log of every chemotherapy drug, dose, and cycle. This medication record is important both for ongoing care and for documenting treatment costs and impacts in a legal claim.